Answers are grounded in this paper and cite their sources.
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
No takes yet. Share an insight, caveat, or question.
Glatman‐Freedman et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: